4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Immunovant, Inc. (IMVT) operates in the Biotechnology industry and is headquartered in Durham, United States with about 315 employees. Its market capitalization is roughly $8 billion. In the fiscal year ended 2026-03-31, IMVT reported $0M in revenue and ($506M) in net income.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($533M) | ($438M) | ($270M) | ($208M) | — |
| Net Income | ($506M) | ($414M) | ($259M) | ($211M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($160M) | ($114M) | ($132M) | ($127M) | ($114M) | — |
| Net Income | ($148M) | ($111M) | ($126M) | ($121M) | ($106M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | $957M | $776M | $666M | $406M | — |
| Total Liabilities | $104M | $69M | $49M | $43M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IMVT viewer.
About TickerBase · Data methodology & sources